Risk of Major Bleeding with Ibrutinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of Major Bleeding with Ibrutinib

Published:2018-11 Issue:11 Volume:18 Page:755-761
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Mock Joseph,Kunk Paul R.,Palkimas Surabhi,Sen Jeremy M.,Devitt Michael,Horton Bethany,Portell Craig A.,Williams Michael E.,Maitland Hillary

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

2. Ibrutinib in previously treated Waldenström’s macroglobulinemia;Treon;N Engl J Med,2015

3. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

4. Targeting BTK with ibrutinib in relapsed/refractory marginal zone lymphoma;Noy;Blood,2017

5. Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024);CHINESE J CANCER RES;2024

2. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

3. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance;International Journal of Hematology;2024-01-09

4. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort;Hematological Oncology;2024-01

5. Pituitary macroadenoma apoplexy as a rare complication of Bruton tyrosine kinase inhibitor in chronic lymphoid leukaemia;Chinese Neurosurgical Journal;2023-10-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3